Treatment of patients with recently exacerbated schizophrenia with paliperidone palmitate: a pilot study of efficacy and tolerability (2020)
- Authors:
- USP affiliated authors: GATTAZ, WAGNER FARID - FM ; ELKIS, HELIO - FM
- Unidade: FM
- DOI: 10.2147/NDT.S233537
- Subjects: ESQUIZOFRENIA; TOLERÂNCIA; PACIENTES; COMPOSTOS HETEROCÍCLICOS; PACIENTES
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Neuropsychiatric disease and treatment
- ISSN: 1178-2021
- Volume/Número/Paginação/Ano: v. 16, p. 2063-2072, 2020
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by-nc
-
ABNT
GATTAZ, Wagner Farid et al. Treatment of patients with recently exacerbated schizophrenia with paliperidone palmitate: a pilot study of efficacy and tolerability. Neuropsychiatric disease and treatment, v. 16, p. 2063-2072, 2020Tradução . . Disponível em: https://doi.org/10.2147/NDT.S233537. Acesso em: 18 set. 2024. -
APA
Gattaz, W. F., Saracco-Alvarez, R., Daltio, C. S., Bilt, M. T. V. de, Ortegon, J. J., Villasenor-Bayardo, S. J., et al. (2020). Treatment of patients with recently exacerbated schizophrenia with paliperidone palmitate: a pilot study of efficacy and tolerability. Neuropsychiatric disease and treatment, 16, 2063-2072. doi:10.2147/NDT.S233537 -
NLM
Gattaz WF, Saracco-Alvarez R, Daltio CS, Bilt MTV de, Ortegon JJ, Villasenor-Bayardo SJ, Louza M, Elkis H, Soares B, Jaramillo PC. Treatment of patients with recently exacerbated schizophrenia with paliperidone palmitate: a pilot study of efficacy and tolerability [Internet]. Neuropsychiatric disease and treatment. 2020 ; 16 2063-2072.[citado 2024 set. 18 ] Available from: https://doi.org/10.2147/NDT.S233537 -
Vancouver
Gattaz WF, Saracco-Alvarez R, Daltio CS, Bilt MTV de, Ortegon JJ, Villasenor-Bayardo SJ, Louza M, Elkis H, Soares B, Jaramillo PC. Treatment of patients with recently exacerbated schizophrenia with paliperidone palmitate: a pilot study of efficacy and tolerability [Internet]. Neuropsychiatric disease and treatment. 2020 ; 16 2063-2072.[citado 2024 set. 18 ] Available from: https://doi.org/10.2147/NDT.S233537 - Aripiprazole for Patients with Schizophrenia and Schizoaffective Disorder: An Open-Label, Randomized, Study Versus Haloperidol
- Decreased S100-beta protein in schizophrenia: preliminary evidence
- Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study
- Algumas recomendações para estudos com placebo
- Esquizofrenia e gênero
- Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia:: a double-blind study
- Ventricular enlargement as a predictor of therapeutic response in schizophrenia: a structural MRI study
- A double blind placebo controlled study of conjugated estrogens added to haloperidol in patients with schizophrenia
- Leonhard´s classification of Schizophrenias and MRI brain abnormalities: preliminary results
- Niacin test in schizophrenia and in major depression
Informações sobre o DOI: 10.2147/NDT.S233537 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
